Cite
Ehteda A, Simon S, Franshaw L, et al. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Rep. 2021;35(2):108994doi: 10.1016/j.celrep.2021.108994.
Ehteda, A., Simon, S., Franshaw, L., Giorgi, F. M., Liu, J., Joshi, S., Rouaen, J. R. C., Pang, C. N. I., Pandher, R., Mayoh, C., Tang, Y., Khan, A., Ung, C., Tolhurst, O., Kankean, A., Hayden, E., Lehmann, R., Shen, S., Gopalakrishnan, A., Trebilcock, P., Gurova, K., Gudkov, A. V., Norris, M. D., Haber, M., Vittorio, O., Tsoli, M., & Ziegler, D. S. (2021). Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell reports, 35(2), 108994. https://doi.org/10.1016/j.celrep.2021.108994
Ehteda, Anahid, et al. "Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG." Cell reports vol. 35,2 (2021): 108994. doi: https://doi.org/10.1016/j.celrep.2021.108994
Ehteda A, Simon S, Franshaw L, Giorgi FM, Liu J, Joshi S, Rouaen JRC, Pang CNI, Pandher R, Mayoh C, Tang Y, Khan A, Ung C, Tolhurst O, Kankean A, Hayden E, Lehmann R, Shen S, Gopalakrishnan A, Trebilcock P, Gurova K, Gudkov AV, Norris MD, Haber M, Vittorio O, Tsoli M, Ziegler DS. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Rep. 2021 Apr 13;35(2):108994. doi: 10.1016/j.celrep.2021.108994. PMID: 33852836.
Copy
Download .nbib